Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
4.230
+0.560 (+15.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
August 03, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
July 19, 2021
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO
Via
Benzinga
Cramer Gives His Opinion On AT&T, Cemex And More
July 11, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is not a fan of AT&T Inc. (NYSE: T). For growth, he would go with T-Mobile Us Inc (NASDAQ: TMUS) and...
Via
Benzinga
Understanding Altimmune's Unusual Options Activity
July 08, 2021
Altimmune (NASDAQ:ALT) shares experienced unusual options activity on Thursday. The stock price moved up to $8.78 following the option alert. Sentiment: BEARISH Option Type:...
Via
Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...
Via
Benzinga
Exposures
Product Safety
Why Altimmune Is Crashing Today
June 30, 2021
The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
Via
The Motley Fool
Exposures
COVID-19
Mid-Afternoon Market Update: Dow Jumps 190 Points; Altimmune Shares Plummet
June 30, 2021
Toward the end of trading Wednesday, the Dow traded up 0.55% to 34,482 while the NASDAQ fell 0.22% to 14,496.86. The S&P also rose, gaining 0.04% to 4,293.57. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
72 Biggest Movers From Yesterday
July 01, 2021
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Wall Street Looks to Wrap Up 2nd Quarter, 1st Half of Year with Gains
June 30, 2021
Stocks are trading near record highs this afternoon, as Wall Street looks to wrap up the second quarter and first half of 2021 with substantial wins.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 30, 2021
Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume...
Via
Benzinga
Mid-Day Market Update: Barnes & Noble Education Drops Following Q4 Results; Aerovate Therapeutics Shares Surge
June 30, 2021
Midway through trading Wednesday, the Dow traded up 0.42% to 34,437.23 while the NASDAQ fell 0.14% to 14,508.18. The S&P also rose, gaining 0.06% to 4,294.30. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Novavax Stock Is Rising Today
June 30, 2021
It could be related to a potential rival's bad news.
Via
The Motley Fool
Exposures
COVID-19
Mid-Morning Market Update: Markets Mostly Higher; General Mills Beats Q4 Views
June 30, 2021
Following the market opening Wednesday, the Dow traded up 0.39% to 34,425.83 while the NASDAQ fell 0.14% to 14,507.82. The S&P also rose, gaining 0.09% to 4,295.71. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
51 Stocks Moving In Wednesday's Mid-Day Session
June 30, 2021
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 30, 2021
Gainers Ocuphire Pharma (NASDAQ:OCUP) shares increased by 63.57% to $7.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
June 30, 2021
Wells Fargo raised the price target for Occidental Petroleum Corporation (NYSE:
Via
Benzinga
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
June 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
31 Stocks Moving in Wednesday's Pre-Market Session
June 30, 2021
Gainers Bridgeline Digital, Inc. (NASDAQ: BLIN) shares rose 83% to $6.20 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume....
Via
Benzinga
Altimmune Stock Tanks On Double Bad News From COVID-19 Program
June 30, 2021
Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges....
Via
Benzinga
Exposures
COVID-19
3 Stocks To Watch Today Based On High Retail-Investor Interest
June 29, 2021
The following stocks are attracting high retail-investor interest on social media early Wednesday. SoFi Technologies I...
Via
Benzinga
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
June 27, 2021
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...
Via
Benzinga
Exposures
Product Safety
48 Biggest Movers From Yesterday
June 17, 2021
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront. Orphazyme A/S...
Via
Benzinga
Altimmune's Stock Trades In A Double Bottom Pattern: What's Next?
June 16, 2021
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that...
Via
Benzinga
Here's Why Altimmune Stock Is Surging Today
June 16, 2021
An experimental new weight loss drug produced compelling data in an early stage clinical trial.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 16, 2021
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 72.49% to $17.34 during Wednesday's regular session. As of 12:31 EST, Orphazyme's stock is trading at a...
Via
Benzinga
Why Altimmune Shares Are Trading Higher Today
June 16, 2021
Altimmune (NASDAQ: ALT) shares are trading higher after the company announced interim data from its ALT-801 Phase 1 trial. Weight loss of 5.4% at 6 weeks was achieved, surpassing...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
June 16, 2021
Gainers Opthea Limited (NASDAQ: OPT) shares surged 50.7% to $13.28. The company recently appointed Mrs. Karen Adams as Vice President of Finance and Company Secretary. Kindred...
Via
Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%
June 16, 2021
Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.